Northstar Group Inc. Acquires 286 Shares of Bristol-Myers Squibb Co (NYSE:BMY)

Northstar Group Inc. boosted its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 4.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,216 shares of the biopharmaceutical company’s stock after purchasing an additional 286 shares during the quarter. Northstar Group Inc.’s holdings in Bristol-Myers Squibb were worth $463,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. Psagot Investment House Ltd. boosted its position in shares of Bristol-Myers Squibb by 4.6% during the 3rd quarter. Psagot Investment House Ltd. now owns 4,038 shares of the biopharmaceutical company’s stock valued at $205,000 after acquiring an additional 178 shares during the last quarter. Jupiter Wealth Management LLC boosted its position in shares of Bristol-Myers Squibb by 2.3% during the 4th quarter. Jupiter Wealth Management LLC now owns 8,180 shares of the biopharmaceutical company’s stock valued at $543,000 after acquiring an additional 180 shares during the last quarter. First National Bank of Omaha boosted its position in shares of Bristol-Myers Squibb by 1.1% during the 4th quarter. First National Bank of Omaha now owns 16,399 shares of the biopharmaceutical company’s stock valued at $1,053,000 after acquiring an additional 185 shares during the last quarter. Archford Capital Strategies LLC boosted its position in shares of Bristol-Myers Squibb by 0.8% during the 4th quarter. Archford Capital Strategies LLC now owns 23,810 shares of the biopharmaceutical company’s stock valued at $1,528,000 after acquiring an additional 189 shares during the last quarter. Finally, Weaver Consulting Group lifted its position in Bristol-Myers Squibb by 3.5% in the third quarter. Weaver Consulting Group now owns 5,906 shares of the biopharmaceutical company’s stock worth $263,000 after buying an additional 200 shares during the last quarter. Institutional investors and hedge funds own 83.35% of the company’s stock.

A number of analysts recently issued reports on BMY shares. Gabelli started coverage on Bristol-Myers Squibb in a research report on Wednesday, November 27th. They issued a “buy” rating for the company. Citigroup upgraded Bristol-Myers Squibb from a “neutral” rating to a “buy” rating and set a $73.00 price target for the company in a research report on Monday, January 6th. Mizuho started coverage on Bristol-Myers Squibb in a research report on Monday, November 25th. They issued a “buy” rating for the company. Morgan Stanley started coverage on Bristol-Myers Squibb in a research report on Friday, November 22nd. They issued an “equal weight” rating and a $60.00 price target for the company. Finally, Bank of America started coverage on Bristol-Myers Squibb in a research report on Wednesday, October 16th. They issued a “buy” rating and a $60.00 price target for the company. One research analyst has rated the stock with a sell rating, three have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $61.69.

BMY stock traded up $0.71 during midday trading on Tuesday, reaching $67.43. The company’s stock had a trading volume of 12,518,638 shares, compared to its average volume of 14,981,600. The company has a debt-to-equity ratio of 1.37, a quick ratio of 3.72 and a current ratio of 3.83. The stock has a fifty day simple moving average of $63.67 and a two-hundred day simple moving average of $53.66. Bristol-Myers Squibb Co has a 1 year low of $42.48 and a 1 year high of $67.62. The firm has a market capitalization of $108.71 billion, a price-to-earnings ratio of 19.43, a PEG ratio of 0.82 and a beta of 0.73.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.17 earnings per share for the quarter, topping analysts’ consensus estimates of $1.06 by $0.11. Bristol-Myers Squibb had a return on equity of 45.49% and a net margin of 23.53%. The business had revenue of $6.01 billion for the quarter, compared to analyst estimates of $5.89 billion. During the same quarter last year, the firm posted $1.09 earnings per share. The business’s revenue was up 5.6% compared to the same quarter last year. As a group, analysts forecast that Bristol-Myers Squibb Co will post 4.34 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd will be paid a $0.45 dividend. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.41. The ex-dividend date is Thursday, January 2nd. This represents a $1.80 dividend on an annualized basis and a yield of 2.67%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 45.23%.

In other Bristol-Myers Squibb news, SVP John E. Elicker sold 15,000 shares of the stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $56.66, for a total value of $849,900.00. Following the sale, the senior vice president now owns 74,471 shares in the company, valued at $4,219,526.86. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Louis S. Schmukler sold 25,000 shares of the stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $56.56, for a total value of $1,414,000.00. Following the completion of the sale, the insider now owns 31,963 shares in the company, valued at approximately $1,807,827.28. The disclosure for this sale can be found here. Company insiders own 0.13% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Article: What is Depreciation?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.